ACE-LY-111

• Research type

  Research Study

• Full title

  A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

• IRAS ID

  245241

• Contact name

  Hendrik-Tobias Arkenau

• Contact email

  Tobias.Arkenau@hcahealthcare.co.uk

• Sponsor organisation

  Acerta Pharma BV

• Eudract number

  2017-004191-63

• Clinicaltrials.gov Identifier

  NCT03527147

• Duration of Study in the UK

  2 years, 5 months, 0 days

• Research summary

  Research Summary

  This is a Phase 1 platform protocol designed to evaluate targeted agents for the treatment of relapsed/refractory aggressive NHL. Each study arm will be conducted in a predefined disease subset. All study arms are open label and allocation to each study arms will not be randomized. Enrolment of subjects into a given study arm will be based on meeting inclusion/exclusion criteria and available slots for that arm.

  There are no control groups, other than historical data, in any of the study arms. The study will be conducted in the United States and the European Union with approximately 25 sites participating.

  Summary of Results

  https://www.astrazenecaclinicaltrials.com/study/ACE-LY-111/

• REC name

  West of Scotland REC 1

• REC reference

  18/WS/0120

• Date of REC Opinion

  13 Aug 2018

• REC opinion

  Further Information Favourable Opinion